Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Karyopharm Therapeutics Inc. issued accompanying warrants to purchase 4,421,518 shares of Common Stock of warrant to RA Capital Management.
- Security
- warrant
- Shares
- accompanying warrants to purchase 4,421,518 shares of Common Stock
- Purchaser
- RA Capital Management
Exact text from the filing
(ii) accompanying warrants to purchase 4,421,518 shares of Common Stock with an exercise price of $10.00 per share (the “Common Stock Warrants”)
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Karyopharm Therapeutics Inc. issued 1,030,354 shares of common stock to RA Capital Management for $6.785 per share.
- Security
- common stock
- Shares
- 1,030,354 shares
- Purchaser
- RA Capital Management
- Consideration
- $6.785 per share
Exact text from the filing
the Company agreed to issue and sell (i) 1,030,354 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $6.785 per share
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Karyopharm Therapeutics Inc. issued pre-funded warrants to purchase up to 3,391,164 shares of Common Stock of warrant to RA Capital Management for $6.7849 per pre-funded warrant.
- Security
- warrant
- Shares
- pre-funded warrants to purchase up to 3,391,164 shares of Common Stock
- Purchaser
- RA Capital Management
- Consideration
- $6.7849 per pre-funded warrant
Exact text from the filing
in lieu of Common Stock, pre-funded warrants to purchase up to 3,391,164 shares of Common Stock (the “Pre-Funded Warrants”) at a purchase price of $6.7849 per pre-funded warrant
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Karyopharm Therapeutics Inc. entered into Securities Purchase Agreement with RA Capital Management valued at gross proceeds of approximately $30 million (effective 2026-03-24).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- RA Capital Management
- Value
- gross proceeds of approximately $30 million
- Effective
- 2026-03-24
Exact text from the filing
On March 24, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with RA Capital Management (the “Investor”), pursuant to which the Company agreed to issue and sell (i) 1,030,354 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $6.785 per share and, in lieu of Common Stock, pre-funded warrants to purchase up to 3,391,164 shares of Common Stock (the “Pre-Funded Warrants”) at a purchase price of $6.7849 per pre-funded warrant, and (ii) accompanying warrants to purchase 4,421,518 shares of Common Stock with an exercise price of $10.00 per share (the “Common Stock Warrants”) to the Investor in a private placement (collectively, the “Private Placement”).
View on SEC.gov